Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma

Intensity Therapeutics (INTS) announced that Christian Meyer M.D., Ph.D., Assistant Professor of Oncology and lead medical oncologist for adult sarcoma patients at Johns Hopkins University’s Sidney Kimmel Cancer Center, presented final safety and efficacy data from the Company’s Phase 1/2 clinical trial of INT230-6 that was used as a monotherapy in patients with relapsed, refractory, and metastatic sarcomas, along with an overview of the Company’s ongoing INVINCIBLE-3 Study design. Phase 1/2 Study: Efficacy: The mOS in the mixed sarcoma population: 21.3 months for INT230-6; The mOS had not been reached with 21.4 months of median follow-up for patients who received a cumulative INT230-6 dose volume that was greater than 40% of their total tumor burden INT230-6 extended overall survival in refractory sarcoma subjects by nearly 15 months as monotherapy when compared to a synthetic control group based on the Royal Marsden Hospital scoring method; Sarcoma population’s overall disease control rate: 93.3% at 2 months; Median duration of response: 4.0 months and 11.3 months for subjects who received a cumulative dose of greater than or equal to 40% of the total incoming total tumor burden INT230-6 demonstrated an increase in T-cells within the tumors. 27% of patients had uninjected tumors shrink, though tumors less than 1 cm were uninjected, untracked and unreported by investigators, so the true abscopal percentage is unknown; further radiomics work is on-going; Safety: INT230-6 demonstrated a favorable safety profile and was well-tolerated; 3 subject had one or more drug regimen-related Grade greater than or equal to 3 Treatment Emergent Adverse Events; all were grade 3